|
Numbers of cases aged 15–24 years, age-standardized rates (per million population) and 95% CIs, average annual percentage rate changes and 95% CIs, by diagnosis, sex and time period and test for sex-difference in temporal trend (P-value) |
|||||||||
| 1968–1980 |
1981–1993 |
1994–2005 |
% Ann Inc |
M/F diff |
|||||
|
|
|||||||||
| CNS tumours |
Male |
87 |
29.0 (22.9,35.1) |
84 |
28.4 (22.3,34.5) |
53 |
23.6 (17.3,30.0) |
-0.5 (-1.9,0.8) |
0.60 |
| Female |
59 |
19.8 (14.7,24.8) |
59 |
20.2 (15.1,25.4) |
47 |
20.8 (14.9,26.8) |
0.0 (-1.5,1.5) |
||
| Ependymomas |
Male |
8 |
2.7 (1.2,5.3) |
10 |
3.4 (1.6,6.3) |
3 |
1.3 (0.3,3.9) |
-2.1 (-5.5,1.4) |
0.19 |
| Female |
2 |
0.7 (0.1,2.5) |
1 |
0.4 (0.0,2.1) |
3 |
1.3 (0.3,3.9) |
3.2 (-3.9,10.3) |
||
| Astrocytomas |
Male |
28 |
9.4 (6.2,13.6) |
25 |
8.6 (5.6,12.7) |
23 |
10.2 (6.5,15.3) |
0.4 (-1.9,2.7) |
0.71 |
| Female |
21 |
7.0 (4.4,10.8) |
17 |
5.8 (3.4,9.3) |
16 |
7.1 (4.0,11.5) |
-0.2 (-2.4,2.0) |
||
| PNET |
Male |
8 |
2.6 (1.1,5.2) |
3 |
1.0 (0.2,2.9) |
2 |
0.9 (0.1,3.2) |
-2.8 (-7.9,2.2) |
0.99 |
| Female |
4 |
1.4 (0.4,3.5) |
2 |
0.7 (0.1,2.5) |
1 |
0.5 (0.0,2.6) |
-2.9 (-8.8,3.1) |
||
| Other gliomas |
Male |
14 |
4.6 (2.5,7.8) |
17 |
5.6 (3.3,9.0) |
5 |
2.2 (0.7,5.2) |
-1.4 (-4.4,1.5) |
0.99 |
| Female |
11 |
3.6 (1.8,6.5) |
10 |
3.6 (1.7,6.7) |
5 |
2.2 (0.7,5.1) |
-1.4 (-5.3,2.4) |
||
| Sympathetic nervous system tumours |
Male |
1 |
0.3 (0.0,1.8) |
6 |
2.1 (0.8,4.6) |
2 |
0.9 (0.1,3.2) |
1.5 (-4.1,7.0) |
0.71 |
| Female |
2 |
0.7 (0.1,2.4) |
3 |
1.1 (0.2,3.1) |
4 |
1.9 (0.5,4.8) |
3.1 (-3.4,9.7) |
||
| Retinoblastoma |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
0 |
- |
0 |
- |
0 |
- |
- |
||
| Renal tumours |
Male |
1 |
0.3 (0.0,1.8) |
3 |
1.0 (0.2,2.9) |
4 |
1.7 (0.5,4.3) |
2.8 (-4.0,9.6) |
0.32 |
| Female |
3 |
1.0 (0.2,3.0) |
3 |
0.9 (0.2,2.7) |
1 |
0.4 (0.0,2.4) |
-1.8 (-7.9,4.3) |
||
| Hepatoblastomas |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
1 |
0.3 (0.0,1.8) |
1 |
0.3 (0.0,1.7) |
0 |
- |
-4.4 (-16.0,7.3) |
||
| Bone tumours |
Male |
36 |
12.1 (8.2,16.1) |
50 |
17.7 (12.8,22.6) |
28 |
12.6 (8.4,18.3) |
0.2 (-1.7,2.0) |
0.15 |
| Female |
19 |
6.4 (3.9,10.0) |
22 |
7.9 (4.9,11.9) |
25 |
11.6 (7.5,17.1) |
2.2 (0.2,4.2) |
||
| Osteosarcoma |
Male |
20 |
6.8 (4.2,10.6) |
23 |
8.2 (5.2,12.3) |
17 |
7.7 (4.5,12.3) |
0.1 (-2.6,2.8) |
0.10 |
| Female |
10 |
3.4 (1.6,6.2) |
12 |
4.3 (2.2,7.5) |
17 |
7.9 (4.6,12.7) |
3.5 (0.5,6.5) |
||
| Ewing's sarcoma |
Male |
9 |
3.0 (1.4,5.7) |
20 |
7.0 (4.3,10.8) |
7 |
3.2 (1.3,6.6) |
1.0 (-1.9,4.0) |
0.50 |
| Female |
6 |
2.1 (0.8,4.5) |
5 |
1.7 (0.6,4.1) |
5 |
2.3 (0.8,5.4) |
-0.7 (-4.8,3.4) |
||
| Soft tissue sarcomas |
Male |
27 |
9.1 (6.0,13.3) |
29 |
9.9 (6.6,14.2) |
33 |
14.6 (9.6,19.6) |
1.9 (-0.4,4.2) |
0.55 |
| Female |
27 |
9.2 (6.1,13.4) |
39 |
13.3 (9.1,17.5) |
28 |
12.7 (8.4,18.4) |
1.0 (-0.8,2.9) |
||
| Rhabdomyosarcoma |
Male |
5 |
1.7 (0.6,4.0) |
2 |
0.7 (0.1,2.6) |
7 |
3.2 (1.3,6.6) |
3.0 (-1.5,7.5) |
0.74 |
| Female |
4 |
1.4 (0.4,3.6) |
13 |
4.6 (2.5,7.9) |
4 |
1.8 (0.5,4.5) |
2.0 (-2.2,6.1) |
||
| Other |
Male |
22 |
7.4 (4.6,11.2) |
27 |
9.1 (6.0,13.3) |
26 |
11.4 (7.5,16.7) |
1.7 (-1.0,4.4) |
0.60 |
| Female |
23 |
7.8 (4.9,11.7) |
26 |
8.7 (5.7,12.7) |
24 |
10.9 (7.0,16.3) |
0.7 (-1.7,3.2) |
||
| Germ cell tumours |
Male |
70 |
23.1 (17.7,28.6) |
115 |
37.5 (30.6,44.4) |
107 |
46.5 (37.7,55.3) |
2.1 (0.6,3.7) |
0.74 |
| Female |
44 |
14.6 (10.3,18.9) |
35 |
11.6 (7.8,15.5) |
48 |
21.6 (15.5,27.7) |
1.7 (-0.2,3.6) |
||
| Gonadal |
Male |
65 |
21.5 (16.2,26.7) |
101 |
32.8 (26.4,39.3) |
94 |
40.9 (32.6,49.1) |
1.9 (0.3,3.4) |
0.51 |
| Female |
29 |
9.6 (6.4,13.8) |
26 |
8.6 (5.6,12.7) |
31 |
13.8 (9.0,18.7) |
1.0 (-1.0,3.0) |
||
| Non-gonadal |
Male |
5 |
1.7 (0.5,3.9) |
14 |
4.6 (2.5,7.8) |
13 |
5.6 (3.0,9.6) |
4.4 (1.1,7.7) |
0.65 |
| Female |
15 |
5.0 (2.8,8.2) |
9 |
3.0 (1.4,5.7) |
17 |
7.8 (4.5,12.4) |
3.2 (-0.7,7.1) |
||
| Carcinomas |
Male |
78 |
25.7 (20.0,31.4) |
75 |
24.6 (19.0,30.2) |
68 |
29.7 (22.6,36.8) |
0.2 (-1.4,1.8) |
0.07 |
| Female |
131 |
43.1 (35.7,50.5) |
164 |
53.9 (45.6,62.1) |
177 |
78.2 (66.7,89.7) |
2.2 (0.7,3.7) |
||
| Thyroid |
Male |
6 |
2.0 (0.7,4.3) |
8 |
2.8 (1.2,5.5) |
9 |
3.9 (1.8,7.4) |
2.5 (-2.2,7.2) |
0.90 |
| Female |
13 |
4.4 (2.3,7.5) |
22 |
7.4 (4.6,11.3) |
26 |
11.5 (7.5,16.9) |
2.8 (0.1,5.6) |
||
| Melanoma |
Male |
20 |
6.7 (4.1,10.4) |
22 |
7.2 (4.5,10.9) |
19 |
8.3 (5.0,13.0) |
0.6 (-2.1,3.3) |
0.03 |
| Female |
25 |
8.3 (5.3,12.2) |
54 |
17.8 (13.0,22.5) |
69 |
30.8 (23.5,38.1) |
4.6 (2.2,7.1) |
||
| Skin |
Male |
9 |
2.9 (1.3,5.5) |
9 |
2.9 (1.3,5.5) |
21 |
9.1 (5.6,13.8) |
4.7 (0.5,8.9) |
0.61 |
| Female |
11 |
3.6 (1.8,6.5) |
12 |
4.1 (2.1,7.1) |
20 |
8.8 (5.4,13.6) |
3.2 (-0.4,6.9) |
||
| Breast |
Male |
0 |
- |
0 |
- |
1 |
0.5 (0.0,2.6) |
11.8 (-8.4,32.0) |
0.25 |
| Female |
14 |
4.5 (2.5,7.6) |
18 |
5.7 (3.4,9.0) |
10 |
4.3 (2.1,8.0) |
-0.3 (-2.9,2.3) |
||
| Genital/other reproductive |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
31 |
10.0 (6.5,13.5) |
28 |
8.8 (5.9,12.8) |
26 |
11.3 (7.4,16.6) |
0.5 (-1.7,2.8) |
||
| Lung and bronchial |
Male |
4 |
1.3 (0.4,3.4) |
3 |
1.0 (0.2,2.9) |
0 |
- |
-6.2 (-12.5,0.2) |
0.23 |
| Female |
2 |
0.7 (0.1,2.4) |
1 |
0.3 (0.0,1.7) |
2 |
0.9 (0.1,3.3) |
0.0 (-7.7,7.8) |
||
| Colorectal |
Male |
10 |
3.3 (1.6,6.1) |
5 |
1.7 (0.6,4.0) |
4 |
1.7 (0.5,4.4) |
-3.5 (-7.4,0.4) |
0.01 |
| Female |
1 |
0.3 (0.0,1.8) |
3 |
1.0 (0.2,2.9) |
5 |
2.2 (0.7,5.0) |
8.2 (0.1,16.3) |
||
|
|
|||||||||
| TOTAL |
Male |
300 |
99.8 (88.5,111.1) |
362 |
121.1 (108.6,133.6) |
295 |
129.7 (114.9,144.5) |
0.8 (-0.2,1.8) |
0.30 |
| Female |
286 |
95.2 (84.1,106.2) |
326 |
109.2 (97.3,121.1) |
330 |
147.2 (131.3,163.1) |
1.6 (0.5,2.7) |
||
|
Figures are counts, ASRs with 95% CIs, Annual Percentage Change in ASR with 95% CIs (estimated from linear regression model) and p value for testing M/F difference in trend (obtained from year *sex interaction term in linear regression model) | |||||||||
Magnanti et al. BMC Cancer 2008 8:89 doi:10.1186/1471-2407-8-89 |
|||||||||